Recent News

• 04.21.2025 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.08.2025 - Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
• 04.01.2025 - Avidity Biosciences to Participate in Upcoming Investor Conference
• 03.31.2025 - Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
• 03.21.2025 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.17.2025 - Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
• 03.17.2025 - 2025 MDA Clinical and Scientific Conference
• 03.12.2025 - Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 8-K Current report
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - EX-99.1 EX-99.1
• 03.17.2025 - 8-K Current report